Valuation: Santhera Pharmaceuticals Holding AG

Market Cap 224M 274M 241M 206M 386M 26.56B 393M 2.68B 1.05B 12.95B 1.03B 1.01B 44.94B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 252M 308M 271M 232M 434M 29.84B 442M 3.01B 1.17B 14.55B 1.16B 1.13B 50.49B EV / Sales 2026 *
2.66x
EV / Sales 2027 * 2.12x
Free-Float
81.19%
Yield 2026 *
-
Yield 2027 * -
1 day-0.27%
1 week-3.28%
Current month-5.99%
1 month-8.09%
3 months-11.08%
6 months+6.65%
Current year+17.14%
1 week 14.48
Extreme 14.48
15.5
1 month 14.42
Extreme 14.42
16.36
Current year 11.7
Extreme 11.7
18.84
1 year 9.38
Extreme 9.38
18.84
3 years 7.14
Extreme 7.14
18.84
5 years 5
Extreme 5
26.6
10 years 5
Extreme 5
820
Manager TitleAgeSince
Chief Executive Officer 50 15/07/2026
Director of Finance/CFO 51 24/02/2025
Chief Operating Officer 55 01/09/2022
Director TitleAgeSince
Chairman 64 30/06/2022
Director/Board Member 58 04/04/2017
Director/Board Member 47 27/06/2023
Date Insider Type Main position Quantity % Market Cap.
22/01/24 Buy 30,228 0.2396%
06/07/23 Buy 2,000 0.0016%
11/01/22 Buy 30,000 0.0549%
Change 5-day change 1-year change 3-year change Capi.($)
-1.34%-3.28%+5.43%+83.13% 275M
+2.53%+2.37%+55.58%+20.10% 315B
+1.72%+0.94%+24.00%-11.62% 67.93B
+2.01%+2.30%+35.46%+85.51% 9.23B
-1.26%-1.72%+4.64%-3.98% 8.43B
+3.78%+1.92%-21.25%-6.67% 4.07B
+0.07%-9.52%-5.52%+22.21% 3.77B
+1.71%+2.73%-42.88%+11.90% 3.54B
+0.73%-1.85%+43.52%+57.47% 2.72B
-0.30%-6.60%+4.82%-10.21% 2.13B
Average +1.08%+0.81%+10.38%+24.78% 41.69B
Weighted average by Cap. +2.28%+3.20%+46.45%+15.71%

Financials

2026 *2027 *
Net sales 94.7M 116M 102M 87.1M 163M 11.22B 166M 1.13B 442M 5.47B 435M 426M 18.99B 116M 141M 124M 106M 199M 13.7B 203M 1.38B 539M 6.68B 531M 519M 23.18B
Net income - -
Net Debt 27.7M 33.9M 29.82M 25.48M 47.78M 3.28B 48.63M 331M 129M 1.6B 127M 125M 5.56B 21.4M 26.19M 23.04M 19.68M 36.91M 2.54B 37.57M 256M 99.81M 1.24B 98.33M 96.2M 4.29B
Logo Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Employees
94
Date Price Change Volume
23/07/26 CHF 14.76 -1.34% 44,077
22/07/26 CHF 14.96 -1.19% 31,383
21/07/26 CHF 15.14 +0.66% 42,194
20/07/26 CHF 15.04 -2.46% 48,321
17/07/26 CHF 15.42 +1.05% 44,449
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
14.96CHF
Average target price
27.50CHF
Spread / Average Target
+83.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANN Stock